Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma

Zheng, Dong; Zhu, Meiling; Li, Qihui; Wan, Wenli; Chen, Yingtong; Jing, Hongmei

doi:10.3390/jcm11216524

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD markers exclusively targeting VSELSCs, such as NANOG/CD44, SSEA4, and CD133, despite their effectiveness for samples directly from the organism [18,21], show lower efficiency in cell lines [19,20]. To ensure consistency in interpreting findings from previous studies [15,16] and to distinguish between different developmental stages within the tested cell lines, we chose CD56 [26][27][28]. Its presence also serves as an indicator of a poorer prognosis in multiple myeloma [27].…”

Section: Introductionmentioning

confidence: 99%

“…To ensure consistency in interpreting findings from previous studies [15,16] and to distinguish between different developmental stages within the tested cell lines, we chose CD56 [26][27][28]. Its presence also serves as an indicator of a poorer prognosis in multiple myeloma [27]. For ALL cells (Jurkat and Raji), the CD56 marker was substituted with CD2 [29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

(Very) Small Stem-like Cells in Human Cell Cultures

Lica,

Pradhan

2023

Cancers

View full text Add to dashboard Cite

Very Small Embryonic-like Stem Cells (VSELSCs) and Very Small Cancer Stem Cells (VSCSCs) are fields of intensive research. Although the presence in vitro of VSELSC and VSCSC cellular stage analogs appear probable, it has yet to be published. Utilizing established human cell cultures with varying populations of primitive cells, stained with CD markers specific to primitive stages, in addition to a fluorescent DNA dye, and following histochemical processing, we have developed a cytological method for detecting Very Small Leukemic Stem-like Cells (VSLSLCs), Very Small Cancer Stem-like Cells (VSCSLCs), and VSELSCs. This detection provides an opportunity to advance research in these areas.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

(Very) Small Stem-like Cells in Human Cell Cultures

Lica,

Pradhan

2023

Cancers

View full text Add to dashboard Cite

show abstract

In Vitro models of leukemia development: the role of very small leukemic stem-like cells in the cellular transformation cascade

Lica,

Jakóbkiewicz-Banecka,

Hellmann

2025

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Recent experimental findings indicate that cancer stem cells originate from transformed very small embryonic-like stem cells. This finding represents an essential advancement in uncovering the processes that drive the onset and progression of cancer. In continuously growing cell lines, for the first time, our team’s follow-up research on leukemia, lung cancer, and healthy embryonic kidney cells revealed stages that resembles very small precursor stem cells. This review explores the origin of leukemic stem-like cells from very small leukemic stem-like cells establish from transformed very small embryonic-like stem cells. We explore theoretical model of acute myeloid leukemia initiation and progresses through various stages, as well basing the HL60 cell line, present its hierarchical stage development in vitro, highlighting the role of these very small precursor primitive stages. We also discuss the potential implications of further research into these unique cellular stages for advancing leukemia and cancer treatment and prevention.

show abstract

Evaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis

Keski,

Merdan,

Zemheri

2024

Tjh

View full text Add to dashboard Cite

Objective Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients. Materials and Methods The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56 + CD117 - , CD56 - CD117 + , CD56 + CD117 + , and CD56 - CD117 - . These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes. Results Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56-positive patients than in CD56-negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56-positive and CD117-positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p<0.001, respectively). High cytogenetic risk was found to be an independent predictor of shorter OS (p>0.001). Conclusion This study’s findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.

show abstract

Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma

Cited by 3 publications

References 28 publications

(Very) Small Stem-like Cells in Human Cell Cultures

(Very) Small Stem-like Cells in Human Cell Cultures

In Vitro models of leukemia development: the role of very small leukemic stem-like cells in the cellular transformation cascade

Evaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis

Contact Info

Product

Resources

About